Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
Key Highlights
- ➤ABI-6250 well tolerated in Phase 1a, with no serious adverse events reported
- ➤ABI-6250 produced dose-dependent, reversible bile-acid increases indicating NTCP target engagement
- ➤Phase 2 chronic HDV studies planned for fourth quarter of 2026
- ➤Phase 2 cholestatic liver disease studies planned for first quarter of 2027
- ➤Pharmacodynamic ABI-6250 analysis recognized as an AASLD Poster of Distinction
Expert Statements
Anuj Gaggar, Chief medical officer of Assembly Bio
“The Phase 1a findings support ABI-6250’s safety profile and demonstrate potent target engagement, and we are pleased the pharmacodynamic analysis was recognized as a Poster of Distinction”
Anuj Gaggar, Chief medical officer of Assembly Bio
“We look forward to sharing these results with the hepatology community as we prepare to advance ABI-6250 into Phase 2 studies in both chronic HDV infection and cholestatic liver diseases.”
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase 1a data from its ABI-6250 program will be presented at The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-9, 2026, in Denver, Colorado.
“The Phase 1a findings support ABI-6250’s safety profile and demonstrate potent target engagement, and we are pleased the pharmacodynamic analysis was recognized as a Poster of Distinction,” said Anuj Gaggar, M.D., Ph.D., chief medical officer of Assembly Bio. “We look forward to sharing these results with the hepatology community as we prepare to advance ABI-6250 into Phase 2 studies in both chronic HDV infection and cholestatic liver diseases.”
Get started
Create a free account to read the full story.